Fibroblast growth factor receptor

Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

Retrieved on: 
Monday, January 3, 2022
MA, NDA, Cancer, Clinical trial, Cisplatin, FDA, File, RNA, Doxorubicin, Ixabepilone, Glioblastoma, RCC, Survival, Ovarian cancer, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Prostate cancer, Partnership, PARP, CEO, Therapy, PMA, Dana–Farber Cancer Institute, Patient, Nasdaq, Program, Adult, Drug development, Allar, Jerusalem, Renal cell carcinoma, Time, Literature, GBM, Osteosarcoma, Fibroblast growth factor receptor, Pharmaceutical industry, Fibroblast growth factor receptor 1

Under the terms of the licensing agreements, Oncoheroes acquires global, exclusive rights to fund and conduct further clinical development of both dovitinib and stenoparib in pediatric cancers.

Key Points: 
  • Under the terms of the licensing agreements, Oncoheroes acquires global, exclusive rights to fund and conduct further clinical development of both dovitinib and stenoparib in pediatric cancers.
  • Oncoheroes will take responsibility for pediatric cancer clinical development activities for both clinical-stage therapeutics.
  • If Allarity does not re-acquire the pediatric field rights, it will further receive certain clinical/regulatory milestone payments and royalties on sales of stenoparib and dovitinib in the pediatric cancer market from Oncoheroes.
  • Steve R. Carchedi, CEO of Allarity Therapeutics, commented, We are very pleased to partner with Oncoheroes Biosciences to advance both dovitinib and stenoparib as potential new therapeutic options for the personalized treatment of children and adolescents with cancer.

AstaReal and University of Tsukuba, Japan awarded Patent on Astaxanthin and Exercise Therapy for Improving Cognitive Function

Retrieved on: 
Wednesday, December 1, 2021
Fibroblast growth factor receptor, Astar Air Cargo, AHN, News, Neuron, Tonian, Insulin, CEO, Katagiri, Brain, Multi-system (rail), Growth factor, Exercise, Memory, Physical therapy, Gene expression, Bureau of Oceans and International Environmental and Scientific Affairs, Blood, University, Cognition, Mouse, Hippocampus, Neurogenesis, View, Research, Adult, Patent, Yook, Learning, University of Tsukuba, IGF1R, Multimedia, Life, Gene, Spatial memory, Quality of life, Toy, Online shopping

AstaReal astaxanthin modulates genes in the brain that are involved in learning, memory and neuron formation.

Key Points: 
  • AstaReal astaxanthin modulates genes in the brain that are involved in learning, memory and neuron formation.
  • Exercise therapy has been shown to stimulate AHN, as well as enhance and help maintain cognitive function.
  • This new patent from AstaReal ( US 11,116732 ) shows that astaxanthin combined with exercise can improve the effects of exercise on AHN, learning, and spatial memory by modulating genetic expression in the hippocampus.
  • Pre -clinical studies led by Prof Hideaki Soya at the University of Tsukuba, showed Astaxanthin combined with exercise improved cognitive function better than either exercise or astaxanthin treatments alone.

Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus

Retrieved on: 
Thursday, November 11, 2021
Cancer, Therapy, Breast, University of Arizona, APP, Clinical trial, Fibroblast growth factor receptor, COVID-19, National Institute, Laboratory, Fatality, NIH, NIAID, Allar, Jerusalem, Dana–Farber Cancer Institute, Severe acute respiratory syndrome coronavirus 2, Research, Social media, Forward-looking statement, Cisplatin, MBio, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Doxorubicin, Patient, CEO, Disease, Degenerative disease, Goal, Northern Arizona University, PARP, Vaccine, Virus, Drug discovery, National Institutes of Health, DNA, Infection, Prostate cancer, RNA, Ixabepilone, Ovarian cancer, Renal cell carcinoma, Company, Pathogen, Antibody, Breast cancer, Center, Nasdaq, Poly (ADP-ribose) polymerase, Pharmaceutical industry

Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (British variant),

Key Points: 
  • Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (British variant),
    Allarity Therapeutics is planning to submit findings to U.S. National Institutes of Health (NIH)
    Hrsholm, Denmark (November 11, 2021) Allarity Therapeutics A/S (Allarity or the Company) today announced positive results from the further pre-clinical testing of the antiviral activity of its oral PARP inhibitor, stenoparib, against Coronavirus variant B.1.617.2 (delta variant).
  • In addition, the Company announced, on August 5, 2021, further pre-clinical tests that had shown stenoparib also inhibits SARS-Cov-2 variants, including alpha variant B.1.1.7 (British variant), beta variant B.1351 (South African variant), and gamma variant P.1 (Brazilian variant).
  • The additional pre-clinical results announced today show that stenoparib demonstrated antiviral activity inhibiting the delta variant in a dose-dependent manner in Vero E6 cells.
  • The delta variant used for the experiments carries an additional deletion in ORF7a, a rapidly spreading mutation.

Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress

Retrieved on: 
Thursday, September 16, 2021
PMA, Ovarian cancer, Fibroblast growth factor receptor, Food, NDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, European Society for Medical Oncology, Confidence interval, Forward-looking statement, Prostate cancer, Allar, Jerusalem, Sorafenib, Patient, ESMO, Confidence, Company, Fibroblast growth factor receptor 1, Nasdaq, Clinical trial, Disease, Renal cell carcinoma, Survival, Doxorubicin, Breast, Breast cancer, Irofulven, Progression-free survival, RNA, PARP, Cisplatin, Ixabepilone, Cancer, Social media, Goal, RCC, Oncology, Pharmaceutical industry

These results validate that the Dovitinib DRP companion diagnostic can identify RCC patients that benefit from treatment with dovitinib when compared to alternative treatment with sorafenib.

Key Points: 
  • These results validate that the Dovitinib DRP companion diagnostic can identify RCC patients that benefit from treatment with dovitinib when compared to alternative treatment with sorafenib.
  • The benefit of dovitinib therapy was also evident in progression-free survival data.
  • Allarity plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for the approval of dovitinib for the treatment of RCC during Q4 2021.
  • We remain committed to bringing novel oncology therapeutics to market, and to patients, together with their DRP companion diagnostics to improve patient outcomes.

Kinnate Biopharma Inc. Presents Preclinical Data on its Lead FGFR Inhibitor Candidate at the JCA-AACR Precision Cancer Medicine International Conference

Retrieved on: 
Monday, September 13, 2021
Risk, Program, U.S. Securities and Exchange Commission, Cancer, Security (finance), Food, UC, SAN, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, Drug discovery, Translational medicine, FGFR, Translational research, Conference, FGFR2, Nasdaq, FGFR3, Clinical trial, IND, Squamous cell carcinoma, SVP, Industry, Therapy, Growth, COVID-19, Medicine, KNTE, Fibroblast growth factor receptor, ICC, GLOBE, SEC, Cholangiocarcinoma, IC50, Pharmaceutical industry

These findings were presented during a virtual poster session at the joint JCA-AACR Precision Cancer Medicine International Conference that took place September 10-12, 2021.

Key Points: 
  • These findings were presented during a virtual poster session at the joint JCA-AACR Precision Cancer Medicine International Conference that took place September 10-12, 2021.
  • Kinnate anticipates filling an Investigational New Drug (IND) application for KIN-3248 with the U.S. Food and Drug Administration (FDA) in the first half of 2022.
  • We are very pleased with the progress of our FGFR program, and these positive preclinical data are an important indicator of the potential anti-tumor activity of KIN-3248, said Eric Martin, Ph.D., SVP, Translational Research and Medicine at Kinnate.
  • Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies.

Allarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus

Retrieved on: 
Thursday, August 5, 2021
Nau, Cisplatin, Cancer, Drug discovery, MBio, MA, Fatality, Clinical trial, Fibroblast growth factor receptor, Irofulven, Polymerase chain reaction, Lineage B.1.1.7, Doxorubicin, Infection, University of Arizona, Plaque, Therapy, Chief executive officer, Northern Arizona University, Laboratory, National Institute, Severe acute respiratory syndrome coronavirus 2, National Institutes of Health, Degenerative disease, Dana–Farber Cancer Institute, App, Breast, RNA, Pathogen, Prostate cancer, Renal cell carcinoma, Company, Research, Student, Forward-looking statement, Allar, Jerusalem, Breast cancer, PARP, Virus, National Institute of Allergy and Infectious Diseases, Patient, COVID-19, Ovarian cancer, Poly (ADP-ribose) polymerase, Ixabepilone, Social media, Center, Nasdaq, DNA, Goal, Disease, Pharmaceutical industry

The Pathogen and Microbiome Institute at Northern Arizona University (NAU), a leading U.S. infectious disease research center, conducted the tests.

Key Points: 
  • The Pathogen and Microbiome Institute at Northern Arizona University (NAU), a leading U.S. infectious disease research center, conducted the tests.
  • The concentration of stenoparib required for virus inhibition was lower in the combination study with remdesivir than in the single agent study.
  • Stenoparib is a novel small molecule (oral), targeted inhibitor of Poly ADP-Ribose Polymerase (PARP), a key DNA damage repair enzyme active in cancer cells.
  • Forward-looking statements include statements concerning Allaritys plans, objectives, goals, future events, performance and/or other information that is not historical information.

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3

Retrieved on: 
Wednesday, July 28, 2021
Tyrosine kinase receptors, Clusters of differentiation, Infectious causes of cancer, Fibroblast growth factor receptor 3, Bladder cancer, Branches of biology, Cancer, Radiation therapy, Physical sciences, Radiation, Fibroblast growth factor receptor, Natural sciences

We have an opportunity to selectively deliver alpha particles to these tumors and use precision radiation therapy as a new treatment paradigm.

Key Points: 
  • We have an opportunity to selectively deliver alpha particles to these tumors and use precision radiation therapy as a new treatment paradigm.
  • While the currently approved pan-FGFR inhibitor for bladder cancer requires the presence of a specific mutation, our approach requires only over-expression of FGFR3.
  • The information that Fusion posts on this website could be deemed to be material information.
  • As a result, Fusion encourages investors, media and others interested to review the information that Fusion posts there on a regular basis.

InnoCare Presents Latest Clinical Data of pan-FGFR Inhibitor Gunagratinib at the 2021 ASCO Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Tyrosine kinase receptors, Fibroblast growth factor receptor, Cell biology, Asco, American Society of Clinical Oncology, Fibroblast growth factor, Biology

InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, presented the latest clinical data for the pan-FGFR inhibitor gunagratinib today at the 2021 American Society of Clinical Oncology (ASCO) annual meeting.

Key Points: 
  • InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, presented the latest clinical data for the pan-FGFR inhibitor gunagratinib today at the 2021 American Society of Clinical Oncology (ASCO) annual meeting.
  • This is the first time InnoCare has presented gunagratinibs clinical data at an international academic conference, showing good safety and tolerability.
  • ICP-192 (gunagratinib), developed by InnoCare Pharma, is a novel pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding.
  • The 2021 ASCO Annual Meeting will be held online from June 4th to 8th, 2021.

Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090

Retrieved on: 
Monday, February 22, 2021
Tyrosine kinase receptors, Clusters of differentiation, Branches of biology, Cell biology, Biology, Fibroblast growth factor receptor 2, Fibroblast growth factor receptor 1, Fibroblast growth factor receptor, Fibroblast growth factor, Tyrosine kinase, Cholangiocarcinoma, Protein kinase inhibitor

In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.

Key Points: 
  • In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.
  • Discovered in-house by Eisai's Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3.
  • et al., "Biliary tract cancer registry in Japan from 2008 to 2013", J Hepatobiliary Pancreat Sci., 2016, 23, 149-157.
  • (6) Arai Y. et al., "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma", Hepatology, 2014, 59, 1427-1434.

Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers

Retrieved on: 
Friday, January 15, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Tyrosine kinase receptors, Clusters of differentiation, Fibroblast growth factor receptor 2, Fibroblast growth factor receptor, Stomatitis, FGFR2b, Gastric Cancer and GEJ Cancer, Five Prime Therapeutics

Stomatitis (31.6% vs 13.0%) and elevated transaminases (34.2% vs 19.5%) were also more common in the bemarituzumab arm.

Key Points: 
  • Stomatitis (31.6% vs 13.0%) and elevated transaminases (34.2% vs 19.5%) were also more common in the bemarituzumab arm.
  • Ocular events are common in therapies targeting FGFR and were also reported in the FIGHT trial.
  • To participate in the conference call, please dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID: 2063209.
  • Bemarituzumab is being developed in gastric and GEJ cancer as a targeted therapy for tumors that overexpress FGFR2b.